Auburn University Professor of Chemistry and Biochemistry Stewart Schneller led a team of researchers in the project, which is expected to be published in an upcoming issue of the journal Bioorganic and Medicinal Chemistry.
Schneller, who has studied Ebola for the past decade, has focused on combatting a variety of virus-caused infections by designing a new drug candidate featuring a compound that may reverse the immune-blocking abilities of certain viruses, including Ebola.
"In simple terms, the Ebola virus has the ability to turn off the body's natural immune response," Schneller said. "We have made a small tweak in compound structure that will turn that response back on."